The lowest target is $136.35 and the highest is $210. The company also successfully completed the acquisition of Syndesi Therapeutics SA in March. Shares of ABBV stock can be purchased through any online brokerage account. I'm on twitter @edmundingham. (AbbVie JPM Healthcare conference presentation). Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. First we can take a quick look at what a forward income statement for AbbVie might look like to 2030. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. Investors needn't panic however - Humira's replacements are expected by AbbVie's CEO to generate even higher revenues per annum. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. The shining star in the aesthetics business is Botox, which increased sales by 45% year over year to $477 million in the first quarter of 2021. AbbVie Inc. is a US-based biopharma company with global operations. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Within eye care, Restasis was a major disappointment, and the entire division seems to be struggling, with total revenues falling from ~$920m in Q2'21, to ~$720m in Q2'22. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. Enjoy your holiday weekend and catch up on our most read stories this week. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. All Rights Reserved. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. Zscaler, Inc Plummets, Is It Time To Buy The Dip? All rights reserved. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska druba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacuticos S.A. de C.V., AbbVie Farmacutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S. r.l., AbbVie Investments Limited, AbbVie Investments S. r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementr GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. This means that . The stock projection varied from the low price target of $135 to the high of $200. Note that analysts ABBV stock forecasts can be wrong. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. Get daily stock ideas from top-performing Wall Street analysts. When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. My No. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. Different trading strategies will suit different investment goals with short or long-term focus. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. The major market events for the week ahead right in your inbox. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. If you rely on the information on this page then you do so entirely on your own risk. RHHBY vs. ABBV: Which Stock Is the Better Value Option? AbbVie Stock Forecast 2023 $165.00 In the last five quarters, AbbVie's Price Target has risen from $122.84 to $162.12 - a 31.98% increase. AbbVie stock is one of the most well-known pharmaceutical companies. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Our daily ratings and market update email newsletter. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. I wrote this article myself, and it expresses my own opinions. One of the few pain points AbbVie experienced during a year of portfolio wide growth in 2022 was the decline in the revenue contribution from Imbruvica, approved to treat various types of lymphoma. These are Immunology, Oncology, Neurology, Virology and Eye Care. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. As such, forecasting stock prices is more of an art than a science. (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. Compare Top Brokerages Here. That was below AbbVie stock analysts' view for $14.16. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. And never invest or trade money you cannot afford to lose. The average price target represents a 6.33% change from the last price of $153.90. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. Data from two Phase 3 induction studies and one maintenance study supported the approval. The median estimate represents a +5.72% increase from the last price of 156.07. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. The official website for the company is www.abbvie.com. Their ABBV share price forecasts range from $140.00 to $200.00. AbbVie projected sales - immunology (my forecasts and assumptions). Pharmaceuticals are often valued based on a philosophy of "jam tomorrow" as opposed to jam today i.e. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. On average, they expect the company's stock price to reach $161.12 in the next twelve months. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. The company didn't offer a . View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. I'm on twitter @edmundingham. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Payout ratios above 75% are not desirable because they may not be sustainable. 67.71% of the stock of AbbVie is held by institutions. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Receive ABBV Stock News and Ratings via Email. To see all exchange delays and terms of use please see Barchart's disclaimer. The pharma industry witnessed solid growth amid the pandemic. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. View ABBV analyst ratings or view top-rated stocks. Disclaimer. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. AbbVie saw a increase in short interest in February. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Receive regular, detailed analysis focused on biotech and healthcare stocks. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. Forecasts shouldnt be used as a substitute for your own research. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. I wrote this article myself, and it expresses my own opinions. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Shares are consolidating with a buy. As such, I have decreased my own expectations for 2022 based on simply doubling H1'22 revenues to get a FY22 figure, and downgrading growth expectations to 3% per annum until 2026. You should consider whether you understand how CFDs work and can afford the risks. As I have mentioned in previous notes, however, the gains owe more to price hikes than sales volumes, and come 2023 and the LOE, even AbbVie admits the blow to revenues will be substantial. What intrigues here is the possibility of RGX-314, an anti-VEGF gene therapy that Gonzalez believes "has the potential to be a one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions". Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. Allergan was a troubled company in many ways, but there is no doubting the strength of its products and pipeline. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. Price target. In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. Skyrizi has shown superiority to Humira in fields such as plaque psoriasis by a statistically significant amount, with a comparable safety profile, whilst Rinvoq has shown superiority in e.g. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. With a 5-year investment, the revenue is expected to be around +88.28%. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. Forecast . The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. I have no business relationship with any company whose stock is mentioned in this article. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Most stock quote data provided by BATS. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. contact@marketbeat.com The analysts 12-month consensus ABBV stock price target was $159.75. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. In-depth profiles and analysis for 20,000 public companies. Having so much debt in a prevailing inflationary environment is also unattractive. Read our dividend analysis for ABBV. If you have an ad-blocker enabled you may be blocked from proceeding. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. The company is focused on research and has a number of collaborations and partnerships to that end. View AbbVie's Short Interest. AbbVie is a leading dividend payer. Skyrizi and Rinvoq will together achieve a higher peak sales figure than even Humira could manage, even while Humira is still making a substantial top line contribution, still accounting for as much of 7% of AbbVie's total sales in 2030. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: Neurology also looks strong although aesthetics, eye care and oncology have something to prove. ABBV Stock 12 Months Forecast. The company reported its first revenue for Botox competitor Daxxify. Is this happening to you frequently? As of February 15th, there was short interest totaling 11,710,000 shares, an increase of 13.7% from the January 31st total of 10,300,000 shares. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. (AbbVie data). As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. 1 dividend stock for a LIFETIME of income. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. AbbVie's stock is owned by many different institutional and retail investors. It . I am not receiving compensation for it (other than from Seeking Alpha). In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. AbbVie product revenues by quarter and year since FY20. It is generally accepted however that 2023 will see the entrants into the US market of several generic versions of Humira - which works by inhibiting Tumor Necrosis Factor ("TNF"), an inflammation causing protein - from the likes of Viatris (VTRS), Organon (OGN), Pfizer (PFE), Amgen (AMGN), and several more companies involved in the development and sale of generic or biosimilar drugs. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. That certainly won't derail the oncology division however. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE.

You Re Probably Wondering How I Got Here Baba O'riley, How Many Beans Are In A 16 Oz Can, Articles A